{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:31:53Z","timestamp":1790285513123,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-5-005"],"award-info":[{"award-number":["2021-I2M-5-005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Enterovirus 71 (EV71) and coxsackieviruses A16 (CA16), A10 (CA10), and A6 (CA6) are the primary pathogens that cause hand, foot, and mouth disease (HFMD). Currently, many manufacturers are developing bivalent, trivalent, and tetravalent vaccines that target these antigens. Cell-based neutralization assay (CBNA), the gold standard for detecting neutralizing antibodies (NtAbs), which are used as indicators of HFMD vaccine efficacy, has several limitations. We aimed to develop a novel assay for detecting NtAbs against a quadrivalent HFMD vaccine. Methods: We developed a four-color pseudovirus-based neutralization assay (PBNA), utilizing fluorescent reporter genes, to rapidly evaluate neutralizing antibodies against EV71, CA16, CA10, and CA6 in multivalent vaccines and compared it with CBNA. Results: PBNA could rapidly and simultaneously detect NtAbs against the four serotypes and required lesser amounts of sera compared to CBNA. A good consistency in determining NtAb titers was observed for PBNA and CBNA. Conclusions: PBNA provides a robust tool for evaluating the efficacy of multivalent HFMD vaccines and conducting seroepidemiological studies.<\/jats:p>","DOI":"10.3390\/vaccines13030320","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:43:51Z","timestamp":1742294631000},"page":"320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Four-Color Pseudovirus-Based Neutralization Assay: A Rapid Method for Evaluating Neutralizing Antibodies Against Quadrivalent Hand, Foot, and Mouth Disease Vaccine"],"prefix":"10.3390","volume":"13","author":[{"given":"Fan","family":"Gao","sequence":"first","affiliation":[{"name":"School of Life Sciences, Tianjin University, Tianjin 300072, China"},{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Vazyme Biotech Co., Ltd., Nanjing 210089, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Vazyme Biotech Co., Ltd., Nanjing 210089, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Liu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Mao","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglun","family":"Liang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-7407","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Tianjin University, Tianjin 300072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, State Key Laboratory of Drug Regulatory Science, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhu, P., Ji, W.-Q., Li, D., Li, Z.-J., Chen, Y., Dai, B.-W., Han, S.-H., Chen, S.-Y., Jin, Y.-F., and Duan, G.-C. (2023). Current status of hand-foot-and-mouth disease. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00908-4"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chen, X.-P., Tan, X.-J., Li, J., Jin, Y., Gong, L.-M., Hong, M., Shi, Y.-L., Zhu, S.-L., Zhang, B.-M., and Zhang, S. (2013). Molecular epidemiology of coxsackievirus A16: Intratype and prevalent intertype recombination identified. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082861"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00430-016-0465-y","article-title":"Hand, foot and mouth disease (HFMD): Emerging epidemiology and the need for a vaccine strategy","volume":"205","author":"Aswathyraj","year":"2016","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wei, S.-H., Huang, Y.-P., Liu, M.-C., Tsou, T.-P., Lin, H.-C., Lin, T.-L., Tsai, C.-Y., Chao, Y.-N., Chang, L.-Y., and Hsu, C.-M. (2011). An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis, 11.","DOI":"10.1186\/1471-2334-11-346"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3201\/eid2410.171953","article-title":"Emerging enteroviruses causing hand, foot and mouth disease, China, 2010\u20132016","volume":"24","author":"Li","year":"2018","journal-title":"Emerg. Infect Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1080\/21645515.2015.1049780","article-title":"Is a multivalent hand, foot, and mouth disease vaccine feasible?","volume":"11","author":"Klein","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1111\/j.1469-0691.2012.03789.x","article-title":"Outbreak of hand, foot and mouth disease\/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: A large citywide, prospective observational study","volume":"18","author":"Mirand","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"B163","DOI":"10.1016\/j.vaccine.2012.10.117","article-title":"A global regulatory science agenda for vaccines","volume":"31","author":"Elmgren","year":"2013","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1016\/j.vaccine.2020.05.001","article-title":"WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines","volume":"38","author":"Lei","year":"2020","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12250-020-00294-3","article-title":"From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD)","volume":"36","author":"He","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1016\/j.vaccine.2018.09.069","article-title":"Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3390\/v7112916","article-title":"Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice","volume":"7","author":"Caine","year":"2015","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.02.008","article-title":"Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles","volume":"129","author":"Liu","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","article-title":"The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease","volume":"36","author":"Lim","year":"2018","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41426-018-0094-1","article-title":"A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity","volume":"7","author":"Zhang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1089\/vim.2020.0073","article-title":"Seroprevalence of Neutralizing Antibodies Against Candidate Serotypes of Enterovirus Vaccines Among Korean Children","volume":"34","author":"Kim","year":"2021","journal-title":"Viral Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3201\/eid2709.204915","article-title":"Seroprevalence and Virologic Surveillance of Enterovirus 71 and Coxsackievirus A6, United Kingdom, 2006\u20132017","volume":"27","author":"Kamau","year":"2021","journal-title":"Emerg. Infect Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1080\/21645515.2019.1691404","article-title":"Development of a Pseudovirus-based assay for measuring neutralizing antibodies against coxsackievirus A10","volume":"16","author":"Li","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wu, X., Mao, Q.-Y., Yao, X., Chen, P., Chen, X.-M., Shao, J., Gao, F., Yu, X., Zhu, F.-C., and Li, R.-C. (2013). Development and evaluation of a Pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064116"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1080\/21645515.2018.1504540","article-title":"A surrogate assay for measuring coxsackievirus A6 neutralizing antibodies","volume":"14","author":"Su","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1080\/21645515.2019.1565266","article-title":"A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge","volume":"15","author":"Du","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Choi, W.-S., Oh, S., Antigua, K.J.C., Jeong, J.H., Kim, B.K., Yun, Y.S., Kang, D.H., Min, S.C., Lim, B.-K., and Kim, W.S. (2023). Development of a universal cloning system for reverse genetics of human enteroviruses. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.03167-22"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4049\/jimmunol.1500918","article-title":"Single-cell analysis of B cell\/antibody cross-reactivity using a novel multicolor fluorospot assay","volume":"195","author":"Hadjilaou","year":"2015","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41564-024-01822-7","article-title":"Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2","volume":"9","author":"Zhu","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41564-018-0319-z","article-title":"Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2","volume":"4","author":"Zhou","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.vaccine.2014.06.025","article-title":"A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice","volume":"32","author":"Ku","year":"2014","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.vaccine.2014.03.012","article-title":"A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses","volume":"32","author":"Cai","year":"2014","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41467-017-00477-9","article-title":"Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody","volume":"8","author":"Xu","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:58Z","timestamp":1760028958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/3\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["vaccines13030320"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13030320","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}